• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测疾病缓解的青少年特发性关节炎患者停用甲氨蝶呤后复发的因素。

Predictive factors of relapse after methotrexate discontinuation in juvenile idiopathic arthritis patients with inactive disease.

机构信息

Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima.

Pediatric Rheumatology Unit, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa.

出版信息

ARP Rheumatol. 2022 Jan-Mar;1(1):12-20.

PMID:35633573
Abstract

OBJECTIVE

To identify predictive factors of relapse after discontinuation of Methotrexate (MTX) in Juvenile Idiopathic Arthritis (JIA) patients with inactive disease.

METHODS

We conducted a prospective multicenter cohort study of patients diagnosed with JIA using real world data from the Portuguese national register database, Reuma.pt. Patients with JIA who have reached JADAS27 inactive disease and discontinued MTX before the age of 18 were evaluated.

RESULTS

A total of 1470 patients with JIA were registered in Reuma.pt. Of the 119 bionaive patients who discontinued MTX due to inactive disease, 32.8% have relapsed. Median time of persistence (using the Kaplan-Meier method and log-rank tests) with inactive disease was significantly higher in patients with more than two years of remission before MTX discontinuation and in those who did not use NSAIDs at time of MTX discontinuation. In Cox regression analyses and after adjustment for age at diagnosis, MTX tapering and JIA category, the use of NSAIDs at the time of MTX discontinuation (HR, 1.98 95%CI 1.03-3.82) and remission time of less than two years before suspension (HR, 3.12 95%CI 1.35-7.13) remained associated with relapse. No association was found between JIA category or the regimen of MTX discontinuation and the risk of relapse.

CONCLUSIONS

In this large cohort we found that the use of NSAIDs at the time of MTX discontinuation was associated with a two times higher likelihood of relapse. In addition, longer duration of remission before MTX withdrawal reduces the chance of relapse in bionaive JIA patients.

摘要

目的

确定处于疾病缓解期的幼年特发性关节炎(JIA)患者停止使用甲氨蝶呤(MTX)后复发的预测因素。

方法

我们进行了一项前瞻性多中心队列研究,纳入了葡萄牙国家登记数据库 Reuma.pt 中的 JIA 患者的真实世界数据。研究对象为达到 JADAS27 疾病缓解且在 18 岁前停止使用 MTX 的 JIA 患者。

结果

Reuma.pt 共登记了 1470 例 JIA 患者。在因疾病缓解而停用 MTX 的 119 例生物制剂初治患者中,有 32.8%复发。使用 Kaplan-Meier 法和对数秩检验进行中位无疾病持续时间(persistence)评估,结果显示在 MTX 停药前缓解时间超过 2 年和 MTX 停药时未使用非甾体抗炎药(NSAIDs)的患者中,疾病缓解持续时间更长。在 Cox 回归分析中,在校正诊断年龄、MTX 减量和 JIA 类型后,MTX 停药时使用 NSAIDs(HR,1.98;95%CI,1.03-3.82)和停药前缓解时间不足 2 年(HR,3.12;95%CI,1.35-7.13)与复发相关。JIA 类型或 MTX 停药方案与复发风险之间未发现关联。

结论

在这项大型队列研究中,我们发现 MTX 停药时使用 NSAIDs 与复发风险增加两倍相关。此外,MTX 停药前缓解时间延长可降低生物制剂初治 JIA 患者的复发几率。

相似文献

1
Predictive factors of relapse after methotrexate discontinuation in juvenile idiopathic arthritis patients with inactive disease.预测疾病缓解的青少年特发性关节炎患者停用甲氨蝶呤后复发的因素。
ARP Rheumatol. 2022 Jan-Mar;1(1):12-20.
2
Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.在停用 MTX 之前处于不活动疾病状态的时间与 JIA 患者的发作风险相关。
Ann Rheum Dis. 2018 Jul;77(7):996-1002. doi: 10.1136/annrheumdis-2017-211968. Epub 2018 Feb 16.
3
Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.生物制剂 DMARDs 在非系统性幼年特发性关节炎患者中的停药:复发率及相关因素的范围回顾。
Pediatr Rheumatol Online J. 2022 Dec 5;20(1):109. doi: 10.1186/s12969-022-00769-5.
4
Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis.青少年类风湿关节炎中氨甲蝶呤治疗的停用
Pediatrics. 1997 Dec;100(6):994-7. doi: 10.1542/peds.100.6.994.
5
Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.药物撤停方法对接受联合治疗的幼年特发性关节炎患者无疾病发作生存期的影响。
Arthritis Care Res (Hoboken). 2015 May;67(5):658-66. doi: 10.1002/acr.22477.
6
Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?甲氨蝶呤治疗幼年特发性关节炎:何时是停药的合适时机?
Ann Rheum Dis. 2004 Feb;63(2):206-8. doi: 10.1136/ard.2003.005686.
7
Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial.幼年特发性关节炎患者采用依那西普和甲氨蝶呤联合治疗可缩短达到疾病无活动状态和缓解的时间:一项双盲安慰剂对照试验的结果。
Pediatr Rheumatol Online J. 2021 Jan 6;19(1):5. doi: 10.1186/s12969-020-00488-9.
8
Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis.甲氨蝶呤治疗与生物初治幼年特发性关节炎患者新发葡萄膜炎发生率降低相关。
RMD Open. 2023 Apr;9(2). doi: 10.1136/rmdopen-2023-003010.
9
Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate.接受依那西普和甲氨蝶呤治疗的幼年特发性关节炎儿童伴随治疗的动态变化。
Pediatr Neonatol. 2019 Oct;60(5):549-555. doi: 10.1016/j.pedneo.2019.02.003. Epub 2019 Feb 22.
10
When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?对于持续性少关节型幼年特发性关节炎患者,何时应考虑使用生物制剂?
Eur J Pediatr. 2024 Jun;183(6):2725-2731. doi: 10.1007/s00431-024-05538-y. Epub 2024 Mar 30.

引用本文的文献

1
Associations of C reactive protein to albumin ratio, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio with disease activity in patients with juvenile idiopathic arthritis.青少年特发性关节炎患者中C反应蛋白与白蛋白比值、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值与疾病活动度的相关性。
BMC Rheumatol. 2024 Jun 17;8(1):26. doi: 10.1186/s41927-024-00390-x.